Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 12 2021
14 12 2021
Historique:
received:
21
01
2021
accepted:
01
11
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
28
1
2022
Statut:
epublish
Résumé
Urinary levels of modified nucleosides reflect nucleic acids turnover and can serve as non-invasive biomarkers for monitoring tumour circadian dynamics, and treatment responses in patients with metastatic colorectal cancer. In 39 patients, median overnight urinary excretion of LC-HRMS determinations of pseudouridine, was ~ tenfold as large as those of 1-methylguanosine, 1-methyladenosine, or 4-acetylcytidine, and ~ 100-fold as large as those of adenosine and cytidine. An increase in any nucleoside excretion after chemotherapy anticipated plasma carcinoembryonic antigen progression 1-2 months later and was associated with poor survival. Ten fractionated urines were collected over 2-days in 29 patients. The median value of the rhythm-adjusted mean of urinary nucleoside excretion varied from 64.3 for pseudouridine down to 0.61 for cytidine. The rhythm amplitudes relative to the 24-h mean of 6 nucleoside excretions were associated with rest duration, supporting a tight link between nucleosides turnover and the rest-activity rhythm. Moreover, the amplitude of the 1-methylguanosine rhythm was correlated with the rest-activity dichotomy index, a significant predictor of survival outcome in prior studies. In conclusion, urinary excretion dynamics of modified nucleosides appeared useful for the characterization of the circadian control of cellular proliferation and for tracking early responses to treatments in colorectal cancer patients.
Identifiants
pubmed: 34907230
doi: 10.1038/s41598-021-03247-2
pii: 10.1038/s41598-021-03247-2
pmc: PMC8671418
doi:
Substances chimiques
Nucleosides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24015Subventions
Organisme : Medical Research Council
ID : MR/M013170/1
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Science. 2010 Oct 15;330(6002):379-85
pubmed: 20947768
Nucleic Acids Res. 1994 Jun 25;22(12):2183-96
pubmed: 7518580
Int J Chronobiol. 1974;2(1):3-16
pubmed: 4843898
Chronobiol Int. 2015;32(7):925-33
pubmed: 26158757
Cancer Lett. 1996 Nov 29;108(2):157-62
pubmed: 8973589
Curr Biol. 2002 Sep 17;12(18):1574-83
pubmed: 12372249
Trends Cell Biol. 2018 May;28(5):368-379
pubmed: 29471986
Chronobiol Int. 2017;34(8):1067-1082
pubmed: 28704069
J Anal Toxicol. 2015 Jun;39(5):335-46
pubmed: 25833899
J Cancer Res Clin Oncol. 1995;121(3):181-8
pubmed: 7713990
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Am J Pathol. 2018 Oct;188(10):2369-2377
pubmed: 30031728
Chronobiol Int. 2014 Oct;31(8):891-900
pubmed: 24927369
Science. 2016 Nov 25;354(6315):994-999
pubmed: 27885004
Clin Chim Acta. 1993 Sep 30;218(2):169-83
pubmed: 7508341
J Natl Cancer Inst. 2005 Apr 6;97(7):507-17
pubmed: 15812076
Anticancer Res. 2018 Nov;38(11):6113-6119
pubmed: 30396926
Clin Chim Acta. 2009 Apr;402(1-2):31-7
pubmed: 19135043
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 15;780(1):27-33
pubmed: 12383477
Curr Biol. 2000 Oct 19;10(20):1291-4
pubmed: 11069111
Clin Biochem. 2009 Apr;42(6):540-3
pubmed: 19186175
BMC Cancer. 2009 Apr 05;9:104
pubmed: 19344524
Annu Rev Pharmacol Toxicol. 2010;50:377-421
pubmed: 20055686
Chronobiol Int. 2018 Feb;35(2):188-197
pubmed: 29144183
Clin Sci (Lond). 2003 Aug;105(2):195-202
pubmed: 12708967
Curr Probl Cancer. 2018 Nov;42(6):593-600
pubmed: 30268335
Biostatistics. 2013 Sep;14(4):792-806
pubmed: 23743206
J Physiol Sci. 2018 May;68(3):207-219
pubmed: 29460036
Sci Rep. 2015 Oct 09;5:14843
pubmed: 26450397
Br J Cancer. 1996 Oct;74(8):1248-52
pubmed: 8883412
J Clin Oncol. 1986 Apr;4(4):607-8
pubmed: 3958771
Curr Hypertens Rep. 2018 May 5;20(5):43
pubmed: 29730779
Theor Biol Med Model. 2014 Apr 11;11:16
pubmed: 24725531
Ann Med. 2014 Jun;46(4):191-207
pubmed: 24915535
J R Soc Interface. 2018 Feb;15(139):
pubmed: 29436510
Sci Rep. 2016 Sep 02;6:32581
pubmed: 27585556
Rapid Commun Mass Spectrom. 2009 Jun;23(11):1543-9
pubmed: 19399767
Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48
pubmed: 20401611
Sleep. 2017 Apr 1;40(4):
pubmed: 28329353
Cancer Med. 2018 Sep;7(9):4396-4405
pubmed: 30088335
Cancer Nurs. 2020 Jan/Feb;43(1):45-51
pubmed: 30299421
Chronobiol Int. 2010 Oct;27(9-10):1911-29
pubmed: 20969531
Br J Cancer. 2006 Jun 5;94(11):1726-33
pubmed: 16685264
Ann Transl Med. 2016 Apr;4(7):136
pubmed: 27162786
PLoS One. 2013 Dec 19;8(12):e81701
pubmed: 24367489
Trends Pharmacol Sci. 2018 Sep;39(9):812-827
pubmed: 30060890
Chronobiol Int. 2002 Mar;19(2):423-39
pubmed: 12025934
Cell Rep. 2012 Apr 19;1(4):341-9
pubmed: 22832226
Science. 2000 Sep 29;289(5488):2344-7
pubmed: 11009419
Clin Ter. 2006 Mar-Apr;157(2):117-22
pubmed: 16817500